

Klaus Seppi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/719223/klaus-seppi-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272
papers

16,093
citations

67
h-index

120
g-index

298
ext. papers

20,078
ext. citations

6.5
avg, IF

6.39
L-index

#	Paper	IF	Citations
272	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. <i>JAMA Neurology</i> , 2022 ,	17.2	3
271	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy.. <i>Clinical Autonomic Research</i> , 2022 , 1	4.3	0
270	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 6-19	2.2	3
269	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. <i>Translational Neurodegeneration</i> , 2022 , 11, 11	10.3	1
268	Undetected ophthalmological disorders in Parkinson's disease.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
267	Neurological outcomes one year after COVID-19 diagnosis: a prospective longitudinal cohort study.. <i>European Journal of Neurology</i> , 2022 ,	6	4
266	Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.. <i>Movement Disorders</i> , 2022 ,	7	2
265	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. <i>Movement Disorders</i> , 2022 ,	7	19
264	Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone: Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. <i>Brain Sciences</i> , 2022 , 12, 661	3.4	1
263	A MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2021 ,	7	4
262	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2021 ,	7	3
261	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021 , 268, 1770-1779	5.5	3
260	Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 155-163	3.6	2
259	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study. <i>Movement Disorders</i> , 2021 , 36, 1464-1466	7	3
258	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson's disease. <i>Sleep</i> , 2021 , 44,	1.1	3
257	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 322-340	2.2	3
256	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2021 , 85, 30-36	3.6	2

255	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021 , 144, 1118-1126	11.2	26
254	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. <i>Annals of Neurology</i> , 2021 , 90, 62-75	9.4	17
253	Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. <i>European Journal of Neurology</i> , 2021 , 28, 3348-3359	6	46
252	Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis. <i>Journal of Neural Transmission</i> , 2021 , 128, 1497-1505	4.3	0
251	Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging. <i>Human Brain Mapping</i> , 2021 , 42, 4809-4822	5.9	3
250	The Parkinson disease connectome - insights from new imaging studies. <i>Nature Reviews Neurology</i> , 2021 , 17, 527-528	15	2
249	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021 , 36, 681-689	7	11
248	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 87-91	3.6	5
247	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 241-245	7	3
246	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye-Tracking Study. <i>Movement Disorders</i> , 2021 , 36, 1246-1250	7	1
245	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021 , 31, 157-164	4.3	5
244	Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
243	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1052-1060	2.2	3
242	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021 , 36, 2703-2705	7	1
241	Factors associated with impaired quality of life three months after being diagnosed with COVID-19. <i>Quality of Life Research</i> , 2021 , 1	3.7	3
240	Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy". <i>Movement Disorders</i> , 2021 , 36, 2208-2209	7	
239	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021 , 36, 1203-1215	7	5
238	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. <i>Movement Disorders</i> , 2020 , 35, 1658-1662	7	3

237	Effects of self-administered cannabidiol in a patient with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020 , 30, 355-356	4.3	2
236	Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report. <i>BMC Neurology</i> , 2020 , 20, 89	3.1	0
235	Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaire. <i>Neurology</i> , 2020 , 94, e1539-e1547	6.5	20
234	Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder. <i>Neurology</i> , 2020 , 94, e1605-e1613	6.5	11
233	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. <i>Annals of Neurology</i> , 2020 , 88, 643-645	9.4	9
232	The footprint of orthostatic hypotension in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 107-109	3.6	1
231	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 57-63	3.6	9
230	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020 , 35, 976-983	7	20
229	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. <i>Parkinsonism and Related Disorders</i> , 2020 , 72, 65-71	3.6	8
228	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 219-228	5.3	12
227	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. <i>European Radiology</i> , 2020 , 30, 2802-2808	8	2
226	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2020 , 70, 51-54	3.6	14
225	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020 , 35, 1745-1750	7	3
224	Time will tell: Decision making in premanifest and manifest Huntington's disease. <i>Brain and Behavior</i> , 2020 , 10, e01843	3.4	5
223	The Frontal Assessment Battery in RLS patients with and without augmentation. <i>Sleep Medicine</i> , 2020 , 75, 456-458	4.6	2
222	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020 , 88, 712-722	9.4	23
221	Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 782-787	2.2	3
220	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020 , 95, e2854-e2865	6.5	8

219	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 750-762	2.2	13
218	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1620-1627	5.3	3
217	Gait and postural disorders in parkinsonism: a clinical approach. <i>Journal of Neurology</i> , 2020 , 267, 3169-3176	5.5	9
216	New hopes for disease modification in Parkinson's Disease. <i>Neuropharmacology</i> , 2020 , 171, 108085	5.5	11
215	Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington's Disease: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2020 , 20, 207-211	2.3	
214	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. <i>CNS Drugs</i> , 2019 , 33, 905-918	6.7	37
213	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 681-691	5.3	10
212	Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. <i>The Lancet Digital Health</i> , 2019 , 1, e222-e231	14.4	27
211	International Guidelines for the Treatment of Huntington's Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 710	4.1	51
210	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019 , 126, 1061-1072	4.3	8
209	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019 , 34, 975-984	7	44
208	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019 , 34, 1041-1048	7	16
207	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 301-309	5.2	14
206	Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. <i>BMC Neurology</i> , 2019 , 19, 50	3.1	44
205	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019 , 58, 23-27	3.6	12
204	Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional study. <i>BMC Neurology</i> , 2019 , 19, 141	3.1	5
203	Comment: Autologous mesenchymal stem cells: Hope for patients with multiple system atrophy?. <i>Neurology</i> , 2019 , 93, 25	6.5	
202	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1926-1928	7	9

201	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019 , 67, 60-65	3.6	13
200	Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 440-441	7	17
199	Imaging markers of disease progression in multiple system atrophy. <i>Future Neurology</i> , 2019 , 14, FNL24	1.5	1
198	Treatment of dementia in Parkinson's disease. <i>The Cochrane Library</i> , 2019 ,	5.2	78
197	Treatment of psychosis in Parkinson's disease. <i>The Cochrane Library</i> , 2019 ,	5.2	78
196	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019 , 149, 137-192	4.4	35
195	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019 , 65, 216-228	5.5	38
194	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. <i>Lancet Neurology</i> , 2019 , 18, 165-176	24.1	50
193	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , 2019 , 34, 180-198	7	357
192	International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1248-1266	7	323
191	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018 , 54, 90-94	3.6	29
190	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 50, 61-68	3.6	42
189	Reflection impulsivity perceptual decision-making in patients with restless legs syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 315-322	5.3	6
188	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 81-87	3.6	17
187	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study. <i>Movement Disorders</i> , 2018 , 33, 405-413	7	33
186	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 83-89	3.6	28
185	Cannabinoids for Treatment of Dystonia in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2018 , 7, 167-173	1.9	19
184	Shaker-related voltage-gated potassium channels Kv1 in human hippocampus. <i>Brain Structure and Function</i> , 2018 , 223, 2663-2671	4	3

183	Sensor-based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018 , 8, e00977	3.4	28
182	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
181	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
180	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 33-40	3.6	14
179	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018 , 90, 74-82	6.5	10
178	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018 , 46, 47-55	3.6	33
177	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
176	Structural Imaging in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2018 , 142, 67-148	4.4	22
175	Leitlinien Chorea/Morbus Huntington für die deutschsprachigen Länder neu bearbeitet. <i>Aktuelle Neurologie</i> , 2018 , 45, 570-585		2
174	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. <i>Neurology</i> , 2018 , 90, 940	6.5	5
173	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 619-623	7	96
172	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 536-544	2.2	38
171	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. <i>Parkinsonism and Related Disorders</i> , 2017 , 40, 1-10	3.6	67
170	Letter re: Incident parkinsonism in older adults without Parkinson disease. <i>Neurology</i> , 2017 , 88, 919	6.5	1
169	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017 , 38, 102-103	3.6	13
168	Consistency of "Probable RBD" Diagnosis with the RBD Screening Questionnaire: A Follow-up Study. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 403-405	2.2	14
167	Very late-onset pure autonomic failure. <i>Movement Disorders</i> , 2017 , 32, 1106-1108	7	3
166	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840

165	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology, The</i> , 2017 , 16, 701-711	24.1	161
164	Magnetic resonance imaging for the diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017 , 124, 915-964	4.3	106
163	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
162	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017 , 32, 510-525	7	65
161	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0189897	3.7	26
160	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017 , 82, 419-428	9.4	108
159	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017 , 32, 1457-1464	7	34
158	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. <i>Journal of Neural Transmission</i> , 2017 , 124, 1029-1036	4.3	10
157	Insulin signalling: new target for Parkinson's treatments?. <i>Lancet, The</i> , 2017 , 390, 1628-1630	40	3
156	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017 , 124, 293-302	4.3	36
155	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 389-396	2.2	3
154	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. <i>PLoS ONE</i> , 2017 , 12, e0174793	3.7	11
153	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. <i>Movement Disorders</i> , 2016 , 31, 1925-1927	7	7
152	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016 , 139, 3163-3169	11.2	57
151	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. <i>Radiology</i> , 2016 , 281, 651-652	20.5	
150	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2016 , 31, 1588-1589	7	
149	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. <i>Neurology</i> , 2016 , 87, 36-40	6.5	29
148	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016 , 123, 439-45	4.3	21

147	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 156-160	2.2	25
146	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 382-388	2.2	4
145	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. <i>Movement Disorders</i> , 2016 , 31, 579-83	7	12
144	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. <i>Movement Disorders</i> , 2016 , 31, 235-40	7	7
143	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. <i>Movement Disorders</i> , 2016 , 31, 1405-8	7	57
142	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2016 , 79, 1026-30	9.4	68
141	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016 , 31, 1577-1581	7	6
140	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. <i>Neurology</i> , 2016 , 87, 2603	6.5	
139	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology</i> , 2016 , 86, 1242-9	6.5	60
138	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1408-13	7	41
137	Predictors for mild parkinsonian signs: a prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 321-4	3.6	21
136	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2015 , 14, 145-52	24.1	69
135	Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study. <i>Journal of Neurology</i> , 2015 , 262, 126-33	5.5	48
134	Mortality in Parkinson's disease: a 38-year follow-up study. <i>Movement Disorders</i> , 2015 , 30, 266-9	7	78
133	Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015 , 85, 1761-8	6.5	94
132	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. <i>Neuroscience Letters</i> , 2015 , 602, 145-9	3.3	34
131	Motoric cognitive risk syndrome: multicenter incidence study. <i>Neurology</i> , 2015 , 85, 388-9	6.5	5
130	The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). <i>Movement Disorders</i> , 2015 , 30, 229-37	7	313

129	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 681-97	5.3	128
128	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 1885-92	7	40
127	Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1974-5	7	5
126	Probable RBD and association with neurodegenerative disease markers: A population-based study. <i>Movement Disorders</i> , 2015 , 30, 1417-21	7	71
125	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. <i>Movement Disorders</i> , 2015 , 30, 1068-76	7	96
124	Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 976-81	7	26
123	Invasive Treatment Strategies in a Patient with PARK 15-Associated Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 434-435	2.2	1
122	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). <i>PLoS ONE</i> , 2015 , 10, e0145493	3.7	13
121	Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. <i>Sleep Medicine</i> , 2015 , 16, 186-9	4.6	67
120	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. <i>Neurology</i> , 2015 , 84, 654-8	6.5	137
119	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014 , 29, 857-67	7	148
118	Risk factors and prodromal markers and the development of Parkinson's disease. <i>Journal of Neurology</i> , 2014 , 261, 180-7	5.5	29
117	Relevance of EARLYSTIM in a tertiary movement disorders center. <i>Movement Disorders</i> , 2014 , 29, 1220-17		5
116	Multiple system atrophy as emerging template for accelerated drug discovery in Synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 793-9	3.6	18
115	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014 , 29, 1774-80	7	58
114	Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. <i>Orphanet Journal of Rare Diseases</i> , 2014 , 9, 161	4.2	67
113	Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 125-127	2.2	1
112	Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. <i>Neurology</i> , 2014 , 82, 1752	6.5	27

111	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014 , 118, 19-35	10.9	33
110	Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. <i>Journal of the Neurological Sciences</i> , 2013 , 332, 21-9	3.2	40
109	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013 , 12, 264-74	24.1	322
108	Structural MRI in Idiopathic Parkinson Disease and Parkinsonism 2013 , 105-128		1
107	Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study. <i>Neurodegenerative Diseases</i> , 2013 , 12, 212-8	2.3	26
106	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. <i>Brain</i> , 2013 , 136, 3028-37	11.2	47
105	Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. <i>International Clinical Psychopharmacology</i> , 2013 , 28, 214-6	2.2	7
104	Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. <i>Epilepsia</i> , 2013 , 54, 495-501	6.4	55
103	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 216-9	7	90
102	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013 , 28, 341-6	7	58
101	Prevalence and burden of gait disorders in elderly men and women aged 60-97 years: a population-based study. <i>PLoS ONE</i> , 2013 , 8, e69627	3.7	103
100	Substantia nigra hypoechogenicity in Friedreich ataxia. <i>Movement Disorders</i> , 2012 , 27, 332-3	7	4
99	The Unified Multiple System Atrophy Rating Scale: intrarater reliability. <i>Movement Disorders</i> , 2012 , 27, 1683-5	7	12
98	Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> , 2012 , 135, 3348-54	8.2	73
97	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012 , 10, 71	2.6	18
96	Drug safety evaluation of rotigotine. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 503-12	4.1	16
95	Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2012 , 7, 83-8	4	10
94	White and gray matter abnormalities in narcolepsy with cataplexy. <i>Sleep</i> , 2012 , 35, 345-51	1.1	30

93	Deep brain stimulation in Huntington's disease: A 4-year follow-up case report. <i>Movement Disorders</i> , 2012 , 27, 806-7; author reply 807-8	7	24
92	Neuroimaging: current role in detecting pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 634-43	7	21
91	Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. <i>Movement Disorders</i> , 2012 , 27, 1194-6	7	13
90	A follow-up study of substantia nigra echogenicity in healthy adults. <i>Movement Disorders</i> , 2012 , 27, 1196-7	7	16
89	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. <i>Movement Disorders</i> , 2012 , 27, 1182-5	7	27
88	Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. <i>Cerebellum</i> , 2012 , 11, 223-6	4.3	17
87	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]ECIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1012-20	8.8	35
86	Video-EEG monitoring: safety and adverse events in 507 consecutive patients. <i>Epilepsia</i> , 2011 , 52, 443-52.4	5.4	69
85	Intensive care management in very old adults: two cases with clostridium tetani infection. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 552-3	5.6	3
84	Pramipexole extended release in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1229-34	4.3	4
83	A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. <i>American Journal of Human Genetics</i> , 2011 , 89, 168-75	11	624
82	A novel computer-assisted image analysis of [123I]ECIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 702-10	8.8	25
81	Axial myopathy in parkinsonism. <i>Movement Disorders</i> , 2011 , 26, 1569-71	7	3
80	The influence of deep brain stimulation on pain perception in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1367-8; author reply 1368-9	7	21
79	The role of arterial spin labeling, a noninvasive MRI perfusion method, in identifying an abnormal cerebral perfusion pattern in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1197-1197	7	0
78	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S2-41	7	397
77	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
76	White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. <i>Annals of Neurology</i> , 2011 , 69, 400-7	9.4	171

75	Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. <i>Archives of Neurology</i> , 2011 , 68, 932-7		131
74	Multiple System Atrophy: Clinical Features and Management. <i>Blue Books of Neurology</i> , 2010 , 34, 340-359		
73	Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. <i>Neuroimaging Clinics of North America</i> , 2010 , 20, 29-55	3	79
72	Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. <i>Neurodegenerative Diseases</i> , 2010 , 7, 300-18	2.3	89
71	Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. <i>Journal of Neurology</i> , 2010 , 257, 638-45	5.5	47
70	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. <i>Lancet Neurology</i> , 2010 , 9, 1070-7	24.1	305
69	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , 2010 , 25, 97-107	7	136
68	Mortality in Parkinson's disease, a 20-year follow-up study. <i>Movement Disorders</i> , 2010 , 25, 661-2	7	11
67	Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1357-63	7	135
66	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010 , 25, 1464-9	7	37
65	Reply: Restless Legs Syndrome and Parkinson's Disease. <i>Movement Disorders</i> , 2010 , 25, 1314-1315	7	
64	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010 , 25, 2604-12	7	155
63	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 2444-9	7	60
62	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. <i>Movement Disorders</i> , 2009 , 24, 949-64	7	119
61	Mortality in Parkinson's disease: a 20-year follow-up study. <i>Movement Disorders</i> , 2009 , 24, 819-25	7	91
60	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009 , 24, 1906-9	7	80
59	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2009 , 24 Suppl 2, S711-20	7	39
58	Restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2076-80	7	100

57	Managing the Non-Motor Symptoms of Parkinson's Disease 2008 , 91-120		1
56	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1093-9	7	168
55	Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. <i>Movement Disorders</i> , 2007 , 22, 174-8	7	9
54	An open trial of levetiracetam for segmental and generalized dystonia. <i>Movement Disorders</i> , 2007 , 22, 1649-51	7	34
53	Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. <i>Movement Disorders</i> , 2007 , 22, 1771-6	7	73
52	Voxel based morphometry reveals specific gray matter changes in primary dystonia. <i>Movement Disorders</i> , 2007 , 22, 1538-42	7	102
51	Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. <i>Movement Disorders</i> , 2007 , 22, 1822-4		29
50	Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2007 , 25, 564-9	5.6	33
49	Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. <i>Journal of Neurology</i> , 2007 , 254, 191-6	5.5	100
48	Predictors of survival in dementia with lewy bodies and Parkinson dementia. <i>Neurodegenerative Diseases</i> , 2007 , 4, 428-30	2.3	58
47	Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. <i>Circulation</i> , 2007 , 116, 385-91	16.7	122
46	MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S400-5	3.6	16
45	Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]beta-CIT SPECT analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 1084-90	8.8	2
44	Seminar on choreas. <i>Lancet Neurology</i> , 2006 , 5, 589-602	24.1	213
43	Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. <i>Movement Disorders</i> , 2006 , 21, 159-65	7	61
42	Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006 , 21, 179-86	7	114
41	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 809-15	7	83
40	Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. <i>Movement Disorders</i> , 2006 , 21, 847-52	7	55

39	Diffusion-weighted imaging in Huntington's disease. <i>Movement Disorders</i> , 2006 , 21, 1043-7	7	35
38	Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. <i>Movement Disorders</i> , 2006 , 21, 1109-13	7	73
37	Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 1281-3	7	24
36	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain</i> , 2006 , 129, 538-42	11.2	108
35	Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. <i>NeuroImage</i> , 2006 , 31, 240-5	7.9	84
34	Parkinson's disease and arithmetics: the role of executive functions. <i>Journal of the Neurological Sciences</i> , 2006 , 248, 124-30	3.2	25
33	Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. <i>Archives of Neurology</i> , 2006 , 63, 1154-60		52
32	Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. <i>Human Genetics</i> , 2006 , 120, 285-92	6.3	36
31	An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. <i>Current Opinion in Neurology</i> , 2005 , 18, 370-5	7.1	84
30	Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. <i>European Heart Journal</i> , 2005 , 26, 279-87	9.5	52
29	Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. <i>Epilepsia</i> , 2005 , 46, 320-3	6.4	28
28	Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurology</i> , 2005 , 4, 815-20	24.1	215
27	Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. <i>Annals of Neurology</i> , 2005 , 58, 630-4	9.4	172
26	Grading of neuropathology in multiple system atrophy: proposal for a novel scale. <i>Movement Disorders</i> , 2005 , 20 Suppl 12, S29-36	7	132
25	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005 , 252, 91-6	5.5	47
24	Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005 , 128, 1605-12	11.2	102
23	Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. <i>Movement Disorders</i> , 2004 , 19, 1320-5	7	30
22	Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004 , 19, 1438-45	7	78

21	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004 , 19, 1391-402	7	372
20	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004 , 21, 1443-51	7.9	127
19	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>NeuroReport</i> , 2004 , 15, 1711-4	1.7	35
18	Clinical and neuropathological correlates of Lewy body disease. <i>Acta Neuropathologica</i> , 2003 , 106, 188-9; author reply 190	14.3	13
17	Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. <i>Movement Disorders</i> , 2003 , 18, 319-323	7	57
16	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003 , 18, 1132-8	7	135
15	Auditory startle response in cervical dystonia. <i>Movement Disorders</i> , 2003 , 18, 1522-6	7	22
14	Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. <i>Clinical Neurophysiology</i> , 2003 , 114, 541-7	4.3	28
13	Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. <i>NeuroImage</i> , 2003 , 20, 1253-63	7.9	27
12	Neuropathologic changes in Parkinson disease with late onset of dementia. <i>Archives of Neurology</i> , 2003 , 60, 452-3; author reply 453-4		4
11	Lewy bodies in patients presenting clinically with Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2002 , 4, 327-8	4.3	3
10	Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Movement Disorders</i> , 2002 , 17, 1041-5	7	39
9	Riluzole therapy in cervical dystonia. <i>Movement Disorders</i> , 2002 , 17, 198-200	7	23
8	Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. <i>Journal of Neurology</i> , 2002 , 249, 835-41	5.5	73
7	Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. <i>Radiology</i> , 2002 , 223, 410-6	20.5	123
6	Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>Journal of Neurology</i> , 2001 , 248, 866-9	5.5	63
5	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): placebo-controlled, polysomnographic case report. <i>Movement Disorders</i> , 2001 , 16, 1177-9		15
4	Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome. <i>Nature Medicine</i> , 2001 , 7, 132	50.5	5

3	Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Experimental Neurology</i> , 2000 , 164, 166-75	5-7	14
2	In vivo magnetic resonance imaging of embryonic neural grafts in a rat model of striatonigral degeneration (multiple system atrophy). <i>NeuroImage</i> , 2000 , 12, 209-18	7-9	11
1	Magnetic resonance imaging of multiple system atrophy	167-203	